[Some immune functions of patients with carcinoma].
To evaluate efficiency of LAK cells from patients with cancer a number of immune functions of patients with advanced carcinoma was investigated. The results showed that: from patients with cancer, lymphocyte transformation (32.83 +/- 52.59), responses of lymphocytes to IL-2 (5.94 +/- 9.31), and to IL-2/PHA (32.25 +/- 43.05), and NK activity (11.18 +/- 6.98), LAK activity (17.86 +/- 9.57) were significantly suppressed (In the healthy donors, the data were 75.70 +/- 52.65, 24.59 +/- 28.25, 125.47 +/- 74.11 respectively, P < 0.001); sIL-2R and TNF concentrations (241.9 +/- 172.5 pmol/L and 1.86 +/- 1.52 ng/ml respectively) in serum from patients with cancer were significantly higher than that of healthy control (134.2 +/- 73.5 pmol/L and 0.63 +/- 0.20 ng/ml respectively, P < 0.05-0.001). Since patients with cancer had suppressed responses of lymphocytes to IL-2, low NK and LAK cell activity, LAK cells from patients with cancer might be less effective than those from healthy donor in the treatment of cancer.
Huang
J S
JS
Laboratory of Clinical Oncology, Navy General Hospital, Beijing.
Liu
W W
WW
Fang
D C
DC
D004938:Esophageal Neoplasms / Q000276:immunology; D006801:Humans; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D007694:Killer Cells, Natural / Q000276:immunology*; D008113:Liver Neoplasms / Q000276:immunology*; D008175:Lung Neoplasms / Q000276:immunology; D008213:Lymphocyte Activation; D015375:Receptors, Interleukin-2 / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D015375:Receptors, Interleukin-2; D014409:Tumor Necrosis Factor-alpha